ClinicalTrials.gg
RecruitingNCT04178174SHORT-OPCUpdated Nov 16, 2026

Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

A Phase 3 interventional study of SABR boost and de-escalated chemoradiation and Standard chemoradiation in Head and Neck Cancer, Oropharynx Cancer and Human Papilloma Virus, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionOropharyngeal NeoplasmsRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Oropharyngeal Neoplasms
Why
  1. The study's listed conditions name Oropharyngeal Neoplasms, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 8 months later.
Updated Nov 16, 2026First site in United States2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Oropharyngeal Neoplasms with a site in Canada — 9 open to participants now, 14 under way, 5 of them phase 3. Oropharyngeal Neoplasms · Canada.

Planned enrollment
4th of 20
360 · median 76
Started
2020
with 1 other
Phase 3
4 of 25
3 open now
Primary completion
2028-12
later than 12 of 13 live
Registered
12th of 25
by date
Lead sponsor
3 of 25
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, this one is the 4th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 12 of the 13 other live ones, and was the 12th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

9 of the 25 studies in Oropharyngeal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Oropharyngeal Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.

Read the detailed description

Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of \~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.

Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.

The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).

This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.

03

Conditions studied

  • Head and Neck Cancer
  • Oropharynx Cancer
  • Human Papilloma Virus

Browse trials for

Keywords

  • head and neck cander
  • Oropharynx cancer
  • Human papilloma virus
  • Radiotherapy
  • Stereotactic body radiotherapy
  • Chemotherapy
  • De-intensification
04

In context

Oropharyngeal Neoplasms Reclassified

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

This study's planned enrollment of 360 is above the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.

Browse Oropharyngeal Neoplasms studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Compared within Oropharyngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Ability to provide written .
  • (ECOG) performance status 0-2.
  • proven diagnosis of squamous cell carcinoma of the oropharynx.
  • Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
  • Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition.
  • Primary tumor \< 30 cc
  • Planned for curative chemoradiation
  • For females of child-bearing age, a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Clinical N3 classification, as per AJCC 8th edition
  • Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction).
  • Previous irradiation of the head and neck region
  • Previous surgery of the HNC region (except for incisional or excisional )
  • Pregnancy or breastfeeding
  • Connective tissue disease
  • Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
  • Non-Cisplatin concurrent chemotherapy
  • Prior induction chemotherapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    SABR boost and de-escalated chemoradiation

    SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.

    Radiation: SABR boost and de-escalated chemoradiation

  • Active comparator
    Standard chemoradiation

    The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.

    Radiation: Standard chemoradiation

Interventions

  • RadiationSABR boost and de-escalated chemoradiation

    Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

  • RadiationStandard chemoradiation

    Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions

07

What researchers measure

Primary outcomes

  1. Progression free survival

    Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation

    Time frame: 2 years after the end of chemoradiation

Secondary outcomes

  1. Subacute toxicity

    Rate of grade ≥ 3 subacute toxicity

    Time frame: Between 2 and 6 months after the end of chemoradiation

  2. Acute toxicity

    Rate of grade ≥ 3 acute toxicity

    Time frame: Less than 2 months after the end of chemoradiation

  3. Late toxicity

    Rate of grade ≥ 3 late toxicity

    Time frame: Between 6 months and 5-years after the end of chemoradiation

  4. OS

    Overall survival

    Time frame: At 2- and 5-years after the end of chemoradiation

  5. locoregional control

    Patient alive with locoregional control

    Time frame: At 2- and 5-years after the end of chemoradiation

  6. Head and neck symptom burden

    Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life.

    Time frame: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation

  7. Dysphagia

    Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life.

    Time frame: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation

  8. Time from treatment start to return to work

    Time from first day of treatment start to first day of return to work.

    Time frame: Measured in days and reported at 2-years post-treatment

08

Study locations

4 of 4 sites recruiting
09

References and documents

Publications

  • Giguere P, Bahig H, Westra S, Roberge D, Bourque JM, Masucci GL, Nkurunziza ES, Freire V, Belliveau C, Duplan D, Vigneault E, Wong P, Lang P, Menard C. Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation. Trials. 2026 Apr 24;27(1):437. doi: 10.1186/s13063-026-09709-0. PubMed 42032732 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Dec 2028, 106 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2019
First posted
Nov 26, 2019
StartActual
Feb 23, 2020
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in United States
Show 2 added (1 United States, 1 Canada)
  • University of Texas MD Anderson Cancer Center · Houston, United States
  • BC Cancer - Kelowna · Kelowna, Canada
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    2 sites added — first site in United States
    Show 2 added (1 United States, 1 Canada)
    • University of Texas MD Anderson Cancer Center · Houston, United States
    • BC Cancer - Kelowna · Kelowna, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04178174
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Feb 23, 2020
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Diane Trudel
Contact
diane.dt.chum@ssss.gouv.qc.ca
514-890-8254
Houda Bahig, MD PhD
study chair · Centre hospitalier de l'Université de Montréal (CHUM)
Phuc-Felix Nguyen-Tan, MD
study chair · Centre hospitalier de l'Université de Montréal (CHUM)
David Palma, MD PhD
principal investigator · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Jack Phan, MD PhD
principal investigator · M.D. Anderson Cancer Center
Khalil Sultanem, MD
principal investigator · Montreal Jewish General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion